Treatment Satisfaction With Ra-223 in Japan
NCT03315260 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85
Last updated 2024-02-08
Summary
This study aims to answer the research question: Are Japanese bone metastatic CRPC patients satisfied with their Ra-223 treatment, and what factors drive such satisfaction? It also aims to determine patient anxiety regarding prostate cancer while on treatment with Ra-223, and assess the effect on quality of life.
Conditions
- Prostatic Neoplasms
Interventions
- DRUG
-
Radium-223 dichloride (Xofigo, BAY88-8223)
Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan)
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 20 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-04-11
- Primary Completion
- 2022-12-01
- Completion
- 2023-03-20
Countries
- Japan
More Related Trials
-
A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before
NCT04587427 ·Status: COMPLETED
-
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
NCT02023697 ·Status: COMPLETED ·Phase: PHASE2
-
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
NCT01934790 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
NCT03563014 ·Status: COMPLETED
-
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
NCT02398526 ·Status: COMPLETED
-
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
NCT04521361 ·Status: COMPLETED ·Phase: PHASE1
-
Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
NCT02450812 ·Status: COMPLETED
-
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
NCT02346526 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body
NCT04281147 ·Status: COMPLETED
-
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
NCT00459654 ·Status: COMPLETED ·Phase: PHASE2
-
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
NCT01516762 ·Status: NO_LONGER_AVAILABLE
-
Radium 223 Following Intermittent ADT
NCT02656563 ·Status: WITHDRAWN ·Phase: PHASE2
-
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
NCT04597125 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
The Combination Therapy With Ra-223 and Enzalutamide
NCT03305224 ·Status: UNKNOWN ·Phase: PHASE2
-
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
NCT03896984 ·Status: COMPLETED
-
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
NCT02043678 ·Status: COMPLETED ·Phase: PHASE3
-
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
NCT02899104 ·Status: COMPLETED
-
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
NCT05301062 ·Status: TERMINATED
-
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
NCT03325127 ·Status: WITHDRAWN
-
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
NCT03304418 ·Status: COMPLETED ·Phase: PHASE2
-
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC
NCT03432949 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
NCT02034552 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
NCT02518698 ·Status: COMPLETED
-
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
NCT04516161 ·Status: COMPLETED
-
PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn
NCT04256993 ·Status: COMPLETED